CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 15, 2005--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it presented pre-clinical data at the 35th Annual Society for Neuroscience Meeting being held in Washington, D.C. from November 12-16, 2005. Alnylam and its academic collaborators presented data from three ongoing neurology programs focused on Parkinson’s disease, Huntington’s disease, and neuropathic pain. “Data emerging from the neuroscience community continues to point to the potential of RNAi therapeutics for the treatment of neurological diseases,” said Victor Kotelianski, M.D., Ph.D., Vice President of Research at Alnylam Pharmaceuticals. “Results from our ongoing pre-clinical studies support the strategy of using siRNAs to treat these diseases. We are excited about the data presented at the Society for Neuroscience meeting, which we believe support an RNAi approach for neurological diseases and demonstrate the progress that Alnylam continues to make in this area.”
